|
Specific adverse events (treatment related) in comparisons with placebo |
||||||
| Number (%) with outcome |
||||||
|
|
||||||
| Dosing (mg) |
Number of trials |
Adverse event |
Sildenafil |
Placebo |
Relative risk (95% CI) |
NNH (95% CI) |
|
|
||||||
| 25 |
3 |
Dyspepsia |
4/312 (1.2) |
1/426 (0.2) |
4.4 (0.6 to 34) |
|
| Headache |
31/312 (10) |
14/426 (3.2) |
3.1 (1.6 to 6.1) |
15 (9.6 to 34) |
||
| Vasodilation |
30/312 (9.6) |
4/426 (1.0) |
11 (3.8 to 29) |
12 (8.3 to 19) |
||
| 50 |
5 |
Dyspepsia |
24/511 (4.7) |
4/607 (0.7) |
6.4 (2.4 to 17) |
24 (17 to 47) |
| Headache |
77/511 (15) |
21/607 (0.3) |
4.5 (2.8 to 7.3) |
8.6 (6.6 to 12) |
||
| Vasodilation |
94/511 (18) |
11/607 (1.8) |
9.7 (5.4 to 18) |
6.0 (5.0 to 7.7) |
||
| 100 |
5 |
Dyspepsia |
60/506 (12) |
4/607 (0.7) |
15 (5.8 to 40) |
8.9 (7.1 to 12) |
| Headache |
115/506 (23) |
21/607 (0.3) |
6.8 (4.3 to 11) |
5.2 (4.3 to 6.5) |
||
| Vasodilation |
90/506 (17) |
11/607 (1.8) |
9.2 (5.0 to 17) |
6.3 (5.1 to 8.0) |
||
| 200 |
2 |
Dyspepsia |
35/191 (18) |
3/181 (1.7) |
11 (3.5 to 35) |
6.0 (4.5 to 9.2) |
| Headache |
62/191 (32) |
7/181 (3.9) |
8.4 (4.0 to 18) |
3.5 (2.8 to 4.7) |
||
| Vasodilation |
43/191 (22) |
7/181 (3.9) |
5.9 (2.7 to 13) |
5.4 (4.0 to 8.3) |
||
| Dose optimised |
5 |
Dyspepsia |
24/517 (4.6) |
7/524 (1.3) |
3.4 (1.5 to 7.9) |
31 (19 to 82) |
| Headache |
63/517 (12) |
10/524 (1.9) |
6.3 (3.2 to 12) |
9.8 (7.5 to 14) |
||
| Vasodilation |
65/517 (13) |
4/524 (0.8) |
16 (6.0 to 44) |
8.5 (6.7 to 11) |
||
Moore et al. BMC Urology 2002 2:6 doi:10.1186/1471-2490-2-6 |
||||||